FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

CIPLA

952.7
-7.45 (-0.78%)
Updated 10:24 22/06 IST

CIPLA Buy or Sell - FrontPage Forums

23 Users have submitted 25 trade ideas of Rs. 3,146,470.91 for CIPLA
Disclaimer
88% Bullish
12% Bearish

CIPLA Buy or Sell - Brokerage Reports

No. of reports in last year
8
No. of analysts
3
Average Consensus Forecast
874.75
Consensus Potential
-11.37%
See CIPLA Share Price Targets >>

CIPLA Ratings

Long term CIPLA rating by FrontPage users
3.6/5 (5 Ratings)
Find answers to all your questions on live CIPLA message board: Is CIPLA buy or sell? Should I buy CIPLA shares? Why are CIPLA shares falling? Should I invest in CIPLA stock?

  1. Home
  2. CIPLA Forum

CIPLA Share Price Discussion

Like
Reply

Type
Buy
Instrument
CIPLA
Entry Price
₹952.5
Price@Trade
₹952.5
Target Price
₹1,053
Stop Price
₹853
Valid Till
Jun 22, 2021 3:20 AM
Margin
₹19,050 approx for 20 Qty
Status
Active
Like
Reply
swap_vert
Trade
Like
Reply
C
Reputation: 0 • Just now

Type
Sell
Instrument
CIPLA
Entry Price
₹951.5
Price@Trade
₹951.5
Target Price
₹947.5
Stop Price
₹955.5
Valid Till
Jun 22, 2021 3:20 AM
Margin
₹95,150 approx for 100 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Sell
Instrument
CIPLA
Entry Price
₹955.3
Price@Trade
₹955.3
Target Price
₹945
Stop Price
₹965
Valid Till
Jun 22, 2021 3:20 AM
Margin
₹95,530 approx for 100 Qty
Status
Active
Like
Reply
swap_vert
Trade
C
Reputation: 2,004 • Yesterday 7:21 AM
Like
Reply

Type
Sell
Instrument
CIPLA
Entry Price
₹958.5
Price@Trade
₹958.5
Target Price
₹948.5
Stop Price
₹968.5
Valid Till
Jun 21, 2021 3:20 AM
Margin
₹479,250 approx for 500 Qty
Status
Exited
Exit Price
₹960.5
Net P&L
-₹1,000 (-0.21%)
Like
Reply (1)
swap_vert
Trade
See all replies
Sowmiya @sowmiya-rJBiLugj_
Yesterday 7:13 AM

Update
Exited
Exit Price
₹960.5
Net P&L
-₹1,000 (-0.21%)

Type
Buy
Instrument
CIPLA JUN21 950 PE
Entry Price
₹7.8
Price@Trade
₹7.8
Target Price
₹15
Stop Price
₹1
Valid Till
Jun 24, 2021 3:20 AM
Margin
₹5,070 approx for 650 Qty
Status
Exited
Exit Price
₹3.7
Net P&L
-₹2,665 (-52.56%)

Like
Reply (1)
swap_vert
Trade
See all replies

Update
Exited
Exit Price
₹3.7
Net P&L
-₹2,665 (-52.56%)

Very gd morning..namaskar adaab...🙏
🙏INTRADAY Stocks commodities and index TREND LEVELS BASED ON ALGO TRADE...🙏
Date: 21st June 2021
Time: 9:10am
Trend:
"NIFTY21JUNFUT LEVELS - Buy at 15646.11 with Target of 15908.51/16020.4 , Add one lot 15611.55 ,Sell at 15576.99 wit...
Read more...
Like
Reply
Like
Reply (2)
See all replies
Parashuram @Tradehunter
Jun 20 1:23 AM

Can take option

SIR WITHOUT KNOWLEDGE DONT BUY MESSAGE ME WHATAPP

CIPLA - chart - 3557077
#CIPLA FUTURE CHART.......ABOVE 966.......GOOD UP MOVE IN THIS COUNTER🎯
Like
Reply

CIPLA - chart - 3556610
#CIPLA Daily Chart
1. you can see 1000+ level in next week sl will be 940
2. cup and handle pattern breakout now its come for retesting
3. full market is down but pharma sector can again shine due to third wave of covid 19
Like
Reply
N
Reputation: 14,612 • Jun 19 4:11 AM
Cipla to tap foreign cos for large-scale vax play
Moving beyond a wide portfolio of Covid drugs and diagnostic kits, the Mumbai-based company — with revenues of nearly Rs 20,000 crore — now plans to partner foreign companies for large-scale fill-and-finish services for coronavirus vaccines.
The Economic Times
Like
Reply
4
Reply (2)
See all replies
Krish K @krishk
Jun 19 11:26 AM

Is it good time to enter in Glenmark, Pizer?
KrisDom Investor @krisdom
Jun 19 11:29 AM

@krishk last leg of the rally in Pharma is pending!
Like
Reply

Type
Buy
Instrument
CIPLA
Entry Price
₹960.25
Price@Trade
₹960.25
Target Price
₹975
Stop Price
₹955
Valid Till
Jun 25, 2021 3:20 AM
Margin
₹480,125 approx for 500 Qty
Status
Exited
Exit Price
₹966.05
Net P&L
+₹2,900 (+0.6%)
Like
Reply (1)
swap_vert
Trade
See all replies
Ajmal shamsudeen @Ajmal12155
Jun 18 8:56 AM

Update
Exited
Exit Price
₹966.05
Net P&L
+₹2,900 (+0.6%)

Type
Buy
Instrument
CIPLA JUN21 960 CE
Entry Price
₹13.65
Price@Trade
₹12.65
Target Price
₹17
Stop Price
₹12
Valid Till
Jun 24, 2021 3:20 AM
Margin
₹8,872.5 approx for 650 Qty
Status
Stoploss Hit
Exit Price
₹12
Net P&L
-₹1,072.5 (-12.09%)

Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 18 7:31 AM

Update
Trade Entered
Entry Price
₹13.65
TrackerBot @trackerbot
Jun 18 7:43 AM

Update
Stoploss Hit
Exit Price
₹12

Type
Buy
Instrument
CIPLA
Entry Price
₹961
Price@Trade
₹961.45
Target Price
₹967
Stop Price
₹958
Valid Till
Jun 25, 2021 3:20 AM
Margin
₹961,000 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹958
Net P&L
-₹3,000 (-0.31%)

Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 18 6:56 AM

Update
Trade Entered
Entry Price
₹961
TrackerBot @trackerbot
Jun 18 7:04 AM

Update
Stoploss Hit
Exit Price
₹958
D
Reputation: 0 • Jun 18 6:19 AM

Type
Buy
Instrument
CIPLA
Entry Price
₹961.5
Price@Trade
₹961
Target Price
₹970
Stop Price
₹955
Valid Till
Jun 25, 2021 3:20 AM
Margin
₹961.5 approx for 1 Qty
Status
Exited before entry

Like
Reply (1)
swap_vert
Trade
See all replies
Datta Kadam @Dkadam
Jun 18 6:20 AM

Update
Exited before entry
Price @ Update
₹960.95

Type
Sell
Instrument
CIPLA
Entry Price
₹958.2  ₹958
Price@Trade
₹958.1
Target Price
₹951.8
Stop Price
₹963.65
Valid Till
Jun 18, 2021 3:20 AM
Margin
₹95,800 approx for 100 Qty
Status
Target Achieved
Exit Price
₹951.8
Net P&L
+₹620 (+0.65%)
Like
Reply (5)
swap_vert
Trade
See all replies

Update
Entry Price Modified
Price @ Update
₹958
Original Entry Price
₹957.55
New Entry Price
₹958
TrackerBot @trackerbot
Jun 18 6:09 AM

Update
Trade Entered
Entry Price
₹958
TrackerBot @trackerbot
Jun 18 8:33 AM

Update
Target Achieved
Exit Price
₹951.8
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CIPLA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization42,645.7
    Enterprise Value42,471.14
    Price to Earnings29.77
    Price to Book Value2.7
    Return on Capital Employed0.13
    Return on Equity0.1
    Face Value2
    Dividend Yield0.01
  • CIPLA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    1-Feb-21Prabhudas LilladherAccumulate913
    1-Feb-21HDFC SecuritiesBuy1,020
    14-Dec-20Prabhudas LilladherBuy887
    14-Dec-20HDFC SecuritiesBuy940
    9-Nov-20Prabhudas LilladherHold836
    CIPLA Brokerage Price Target
  • CIPLA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jun 21958962.7950.5960.15
    Jun 18950.95967.65945.35960.9
    Jun 17955959.75943.5950.95
    Jun 16969971.15953.8956.75
    Jun 15975978.85967.15969.7
  • CIPLA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹953.57
    30 Day Moving Average₹937.24
    50 Day Moving Average₹924.94
    100 Day Moving Average₹869.71
    200 Day Moving Average₹821.4
  • CIPLA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue11,39010,974.580.04
    Operating Profit2,1181,596.260.33
    Profit Before Tax1,9111,186.940.61
    Net Income1,469974.940.51
  • CIPLA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds15,78214,1140.12
    Total Liabilities2,6373,497-0.25
    Total Assets18,41917,6100.05
  • CIPLA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,1172,205.56-0.49
    Cash from Investing Activity-593-1,191.75-0.5
    Cash from Financing Activity-351-1,008.97-0.65
    Net Cash Flow1734.8434.74
  • CIPLA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.06
    Return on Equity0.10.08
    Return on Capital Employed0.130.09
  • CIPLA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.12
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.16
    3 Year CAGR Growth in Net Income0.24
    3 Yr CAGR Growth - Diluted EPS0.24
  • CIPLA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.39
    5 Year CAGR Growth in Operating ProfitNA
    5 Year CAGR Growth in EBIDTA0.05
    5 Year CAGR Growth in Net Income-0.03
    3 Yr CAGR Growth - Diluted EPS-0.03
  • CIPLA - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 19 4:11 AM
    Cipla to tap foreign cos for large-scale vax play
    The Economic Times
    NewsBot
    Jun 17 1:51 AM
    Bombay HC asks Maharashtra government to find out how Sonu Sood and MLA Zeeshan Siddique procured anti-Covid drugs
    The Economic Times
    NewsBot
    Jun 1 10:51 AM
    COVID-19: Antibody cocktail treatment begins at Delhi's Sir Ganga Ram Hospital
    The Economic Times
    NewsBot
    May 31 3:26 AM
    Close to commit over $1-bn to Moderna for COVID-19 booster vaccine; Provide price capping waiver, indemnity: Cipla to Govt
    The Economic Times
    NewsBot
    May 30 3:11 AM
    72-year-old Covid patient given 'antibody cocktail' at Fortis in Mohali
    The Economic Times
    NewsBot
    May 27 3:31 AM
    India's Zydus Cadila seeks human trial approval for COVID-19 antibody cocktail
    The Economic Times
    NewsBot
    May 24 7:26 AM
    Cipla to market Roche's Antibody Cocktail in India
    The Economic Times
    NewsBot
    May 20 4:36 AM
    Cipla launches RT-PCR test kit 'ViraGen' in India partnership with Ubio Biotech
    The Economic Times
    NewsBot
    May 18 7:31 AM
    Core portfolio of Cipla very strong, momentum intact: Umang Vohra
    The Economic Times
    NewsBot
    May 17 4:41 AM
    Remdesivir production capacity increased to around 1.19 cr crore vials a month: Govt
    The Economic Times
  • CIPLA - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • CIPLA - More Information

    keyboard_arrow_down

    Cipla Ltd:
    Cipla Limited, along with its multiple subsidiaries, is responsible for the manufacture and sale of pharmaceutical goods in India. It provides a variety of formulations and active pharmaceutical ingredients in various aspects like urology, ophthalmology, malaria, oncology, neurosciences, women’s and children’s health, hepatitis, critical care, osteoporosis, and infectious diseases.
    The company provides multiple inhalation therapy devices like nasal sprays, metered-dose inhalers, accessory devices, dry powder inhalers, and nebulizers. Apart from manufacturing and selling these products in India, it also exports to Russia, the Middle East, Asia, Australia, New Zealand, and Latin America and other regions internationally.
    On 17th of August in 1935, Cipla got registered as a public limited with a capital of Rs. 6 lakh and is a Mumbai based Company in India. During the Second World War, when the drug supplies were topped in 1941, the company started to produce fine chemicals. At this point, Cipla dedicated its facilities to provide a variety of ingenious drugs.
    About Company Information:
    Within the next two decades after the inception of the Second World War, in 1960, the company started its operations in Vikhroli, Mumbai. This was their second plant. At this unit, they produced fine chemicals related to natural products. Ampicillin was manufactured for the first time in the country in 1968 by Cipla. To cultivate medicinal plants, the company then started their Agricultural Research Division, located in Bangalore, in the year 1972.
    In 1982, the company started operating in its fourth manufacturing unit located in Patalganga, Maharashtra. The company collaborated with the National Chemical Laboratory in Pune, in the year 1984 to produce anti-cancer drugs like vincristine and vinblastine. Collaborating with Indian Institute of Chemical Technology, in 1991, a drug considered to be a breakthrough in chemotherapy, named etoposide was launched by the company. Later on, an antiretroviral drug called zidovudine was also manufactured by the company in association with Indian Institute of Chemical Technology.
    Nevirapine, an antiretroviral drug used to stop AIDS transmission in a child from a mother, was launched by the company in 1999. Cipla was the first company, outside of Europe and U.S.A, which began CFC-free-inhalers, in the year 2000. In February in 2007, the company allied with the Drugs for Neglected Diseases Initiative for developing a new anti-malarial drug. This was a worldwide initiative taken by the company with a non-profit organization like DNDI.
    In April of 2010, the company started its operations for commercial production of a variety of pharmaceutical formulations at their SEZ project in Indore, MP. On the 21st of July, 2012, Cipla revealed that they were to collaborate with DNDi (a non-profit R&D organization) for developing an improved form of antiretroviral (ARV) combo therapy which will specifically treat kids affected by HIV/AIDS.
    On the 17th of April, 2013, Cipla announced that they would be the first to launch a biosimilar of Etanercept in the country which will be targeted to treat rheumatic disorders. On the 20th of February in 2014, Cipla announced their alliance with MSD which would give them a non-exclusive license using which they would sell raltegravir 400mg tablet (a drug from MSD) along with marketing and distribution of the drug but down under a different brand name.
    In February 2015, Cipla revealed to have been awarded a Global Fund ARV Tender which is worth USD 188.95 million for developing antiretroviral drugs.
    On the 12th of October, 2016, Cipla announced the formal closing of US FDA inspection that was conducted in July-August in the year 2015. Cipla was given the establishment inspection report by the FDA, and it was held AT THE Indore Unit of the company. On the 30th of November, 2017, Cipla publicized the fact that the company had received approval from the World Health Organization (WHO) for a product name Q-TIB, which is essentially a combination of novel fixed-dose within a single tablet form. This was the first combination to ever exist in the world.
    How Cipla Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cipla Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cipla Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020